bluebird bio, Inc. (BLUE)
Data as of , from SEC Form 4 filings.
See up to 3 months of BLUE. The 7-day demo opens the 1M and 3M ranges and puts BLUE on your watchlist.
Start 7-day demoLatest BLUE insider trades
About bluebird bio, Inc. (BLUE)
bluebird bio, Inc. files with the SEC under CIK 0001293971 and is classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
BLUE Form 4 activity by transaction type, last 90 days
No Form 4 activity for BLUE in the last 90 days.
BLUE insider transactions (Form 4)
5827 Form 4 filings on record, the earliest from Oct 2, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Joseph Vittiglio - Officer | Other | Common Stock | 1,143 | - | - | |
| Joseph Vittiglio - Officer | Derivative | Common Stock | 3,125 | - | - | |
| Joseph Vittiglio - Officer | Grant or award | Common Stock | 2,500 | - | - | |
| Joseph Vittiglio - Officer | Derivative | Common Stock | 2,500 | - | - | |
| John O. Agwunobi | Other | Common Stock | 1,323 | - | - | |
| John O. Agwunobi | Derivative | Common Stock | 1,245 | - | - | |
| Mark Vachon | Other | Common Stock | 1,252 | - | - | |
| Mark Vachon | Derivative | Common Stock | 1,245 | - | - | |
| Richard A. Colvin - Officer | Other | Common Stock | 3,552 | - | - | |
| Richard A. Colvin - Officer | Derivative | Common Stock | 4,166 | - | - | |
| Richard A. Colvin - Officer | Grant or award | Common Stock | 2,500 | - | - | |
| Richard A. Colvin - Officer | Derivative | Common Stock | 2,500 | - | - | |
| Najoh Tita-Reid | Other | Common Stock | 1,163 | - | - | |
| Najoh Tita-Reid | Derivative | Common Stock | 1,245 | - | - | |
| Andrew Obenshain - Officer | Other | Common Stock | 9,027 | - | - | |
| Andrew Obenshain - Officer | Derivative | Common Stock | 9,300 | - | - | |
| Andrew Obenshain - Officer | Grant or award | Common Stock | 14,820 | - | - | |
| Andrew Obenshain - Officer | Derivative | Common Stock | 14,820 | - | - | |
| Charlotte Jones-Burton | Other | Common Stock | 928 | - | - | |
| Charlotte Jones-Burton | Derivative | Common Stock | 1,245 | - | - | |
| Elisabeth Leiderman | Other | Common Stock | 1,112 | - | - | |
| Elisabeth Leiderman | Derivative | Common Stock | 1,245 | - | - | |
| Thomas J. Klima - Officer | Other | Common Stock | 3,414 | - | - | |
| Thomas J. Klima - Officer | Derivative | Common Stock | 4,464 | - | - | |
| Thomas J. Klima - Officer | Grant or award | Common Stock | 2,500 | - | - | |
| Thomas J. Klima - Officer | Derivative | Common Stock | 2,500 | - | - | |
| Nick Leschly | Other | Common Stock | 14,416 | - | - | |
| Nick Leschly | Other | Common Stock | 2,284 | - | - | |
| Nick Leschly | Other | Common Stock | 6,150 | - | - | |
| Nick Leschly | Derivative | Common Stock | 1,245 | - | - | |
| O. James Sterling - Officer | Derivative | Common Stock | 5,000 | - | - | |
| O. James Sterling - Officer | Grant or award | Common Stock | 2,500 | - | - | |
| O. James Sterling - Officer | Derivative | Common Stock | 2,500 | - | - | |
| Michael Cloonan | Derivative | Common Stock | 1,867 | - | - | |
| Andrew Obenshain - Officer | Open-market sale | Common Stock | 971 | $8.35 | $405 | |
| Richard A. Colvin - Officer | Open-market sale | Common Stock | 2,824 | $8.35 | $1K | |
| Najoh Tita-Reid | Grant or award | Common Stock | 24,900 | $0.00 | - | |
| Najoh Tita-Reid | Grant or award | Stock Option (right to buy) | 49,850 | $0.00 | - | |
| Nick Leschly | Grant or award | Common Stock | 24,900 | $0.00 | - | |
| Nick Leschly | Grant or award | Stock Option (right to buy) | 49,850 | $0.00 | - | |
 Richard A. Paulson | Grant or award | Common Stock | 24,900 | $0.00 | - | |
| Richard A. Paulson | Grant or award | Stock Option (right to buy) | 49,850 | $0.00 | - | |
| Charlotte Jones-Burton | Grant or award | Common Stock | 24,900 | $0.00 | - | |
| Charlotte Jones-Burton | Grant or award | Stock Option (right to buy) | 49,850 | $0.00 | - | |
| John O. Agwunobi | Grant or award | Common Stock | 24,900 | $0.00 | - | |
| John O. Agwunobi | Grant or award | Stock Option (right to buy) | 49,850 | $0.00 | - | |
| Elisabeth Leiderman | Grant or award | Common Stock | 24,900 | $0.00 | - | |
| Elisabeth Leiderman | Grant or award | Stock Option (right to buy) | 49,850 | $0.00 | - | |
| Mark Vachon | Grant or award | Common Stock | 24,900 | $0.00 | - | |
| Mark Vachon | Grant or award | Stock Option (right to buy) | 49,850 | $0.00 | - | |
| Richard A. Colvin - Officer | Grant or award | Common Stock | 50,000 | $0.00 | - | |
| Joseph Vittiglio - Officer | Grant or award | Common Stock | 50,000 | $0.00 | - | |
| Michael Cloonan | Grant or award | Common Stock | 37,350 | $0.00 | - | |
| O. James Sterling - Officer | Grant or award | Common Stock | 100,000 | $0.00 | - | |
| Thomas J. Klima - Officer | Grant or award | Common Stock | 50,000 | $0.00 | - | |
| Thomas J. Klima - Officer | Open-market sale | Common Stock | 1,006 | $10.51 | $529 | |
| Andrew Obenshain - Officer | Grant or award | Common Stock | 130,000 | $0.00 | - | |
| Andrew Obenshain - Officer | Open-market sale | Common Stock | 34,780 | $10.51 | $18K |
BLUE insider trading FAQ
What is the latest insider trade for BLUE?
bluebird bio, Inc. (BLUE) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-06-03. The full record for BLUE runs to 27 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying BLUE stock?
No insider purchases of BLUE were filed in the last 90 days.
How many insiders are selling BLUE stock?
No insider sales of BLUE were filed in the last 90 days. 4 sales are on record for this company.
Where can I see BLUE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects BLUE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Joseph Vittiglio view on EDGAR
- - John O. Agwunobi view on EDGAR
- - Mark Vachon view on EDGAR
- - Richard A. Colvin view on EDGAR
- - Najoh Tita-Reid view on EDGAR
- - Andrew Obenshain view on EDGAR
- - Charlotte Jones-Burton view on EDGAR
- - Elisabeth Leiderman view on EDGAR
- - Thomas J. Klima view on EDGAR
- - Nick Leschly view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where BLUE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow BLUE with a 7-day demo
- BLUE on your watchlist
- Every BLUE Form 4 filing on record
- Up to 3 months of BLUE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
